- Home
- CURV vs DTIL Comparison
CURV vs DTIL Comparison
Compare CURV & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURV | DTIL |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 185.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CURV | DTIL |
|---|---|---|
| Price | $2.15 | $8.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $1.59 | ★ $45.00 |
| AVG Volume (30 Days) | 281.4K | ★ 623.8K |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,092,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $3.53 |
| 52 Week High | $2.88 | $9.62 |
Technical Indicators
Market Signals| Indicator | CURV | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 64.72 | 65.96 |
| Support Level | $1.03 | $6.30 |
| Resistance Level | $2.23 | $9.62 |
| Average True Range (ATR) | 0.17 | 0.67 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 75.32 | 75.29 |
Price Performance
Historical ComparisonAbout CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).